Hypocretins regulate the anxiogenic-like effects of nicotine and induce reinstatement of nicotine-seeking behavior

J Neurosci. 2010 Feb 10;30(6):2300-10. doi: 10.1523/JNEUROSCI.5724-09.2010.

Abstract

Emerging evidence suggests that the hypocretinergic system is involved in addictive behavior. In this study, we investigated the role of these hypothalamic neuropeptides in anxiety-like responses of nicotine and stress-induced reinstatement of nicotine-seeking behavior. Acute nicotine (0.8 mg/kg, s.c.) induced anxiogenic-like effects in the elevated plus-maze and activated the paraventricular nucleus of the hypothalamus (PVN) as revealed by c-Fos expression. Pretreatment with the hypocretin receptor 1 (Hcrtr-1) antagonist SB334867 or preprohypocretin gene deletion blocked both nicotine effects. In the PVN, SB334867 also prevented the activation of corticotrophin releasing factor (CRF) and arginine-vasopressin (AVP) neurons, which expressed Hcrtr-1. In addition, an increase of the percentage of c-Fos-positive hypocretin cells in the perifornical and dorsomedial hypothalamic (PFA/DMH) areas was found after nicotine (0.8 mg/kg, s.c.) administration. Intracerebroventricular infusion of hypocretin-1 (Hcrt-1) (0.75 nmol/1 mul) or footshock stress reinstated a previously extinguished nicotine-seeking behavior. The effects of Hcrt-1 were blocked by SB334867, but not by the CRF1 receptor antagonist antalarmin. Moreover, SB334867 did not block CRF-dependent footshock-induced reinstatement of nicotine-seeking while antalarmin was effective in preventing this nicotine motivational response. Therefore, the Hcrt system interacts with CRF and AVP neurons in the PVN and modulates the anxiogenic-like effects of nicotine whereas Hcrt and CRF play a different role in the reinstatement of nicotine-seeking. Indeed, Hcrt-1 reinstates nicotine-seeking through a mechanism independent of CRF activation whereas CRF mediates the reinstatement induced by stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anxiety / metabolism
  • Anxiety / physiopathology
  • Anxiety / psychology*
  • Arginine Vasopressin / metabolism
  • Behavior, Addictive / metabolism
  • Behavior, Addictive / physiopathology
  • Behavior, Addictive / psychology*
  • Benzoxazoles / pharmacology
  • Conditioning, Operant / drug effects
  • Corticotropin-Releasing Hormone / metabolism
  • Extinction, Psychological
  • Intracellular Signaling Peptides and Proteins / genetics
  • Intracellular Signaling Peptides and Proteins / physiology*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Naphthyridines
  • Neurons / metabolism
  • Neuropeptides / genetics
  • Neuropeptides / physiology*
  • Nicotine / administration & dosage
  • Nicotine / pharmacology*
  • Orexin Receptors
  • Orexins
  • Paraventricular Hypothalamic Nucleus / drug effects
  • Paraventricular Hypothalamic Nucleus / metabolism
  • Paraventricular Hypothalamic Nucleus / physiopathology
  • Pyrimidines / pharmacology
  • Pyrroles / pharmacology
  • Receptors, Corticotropin-Releasing Hormone / antagonists & inhibitors
  • Receptors, G-Protein-Coupled / antagonists & inhibitors
  • Receptors, Neuropeptide / antagonists & inhibitors
  • Self Administration
  • Tobacco Use Disorder / metabolism
  • Tobacco Use Disorder / physiopathology
  • Tobacco Use Disorder / psychology*
  • Urea / analogs & derivatives
  • Urea / pharmacology

Substances

  • 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea
  • Benzoxazoles
  • Intracellular Signaling Peptides and Proteins
  • Naphthyridines
  • Neuropeptides
  • Orexin Receptors
  • Orexins
  • Pyrimidines
  • Pyrroles
  • Receptors, Corticotropin-Releasing Hormone
  • Receptors, G-Protein-Coupled
  • Receptors, Neuropeptide
  • antalarmin
  • Arginine Vasopressin
  • CRF receptor type 1
  • Nicotine
  • Urea
  • Corticotropin-Releasing Hormone